Form 4: Pacira BioSciences Director Abraham Ceesay Acquires Shares and Stock Options

Director Abraham Ceesay acquired 5,230 shares of common stock and 12,179 stock options in Pacira BioSciences on June 12, 2024.

Summary

• On June 12, 2024, Abraham Ceesay, a director of Pacira BioSciences, acquired 5,230 shares of common stock.
• These shares were acquired at a price of $0.
• Following the transaction, Ceesay directly owns 5,230 shares of Pacira BioSciences common stock.
• Ceesay also acquired 12,179 stock options with an exercise price of $28.68.
• These options are exercisable starting June 12, 2025, and expire on June 12, 2034.
• The restricted stock units vest on June 12, 2025, contingent upon continued service with the issuer.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying can be a positive signal, but the document is primarily a regulatory filing.

Positives

• A director's acquisition of shares and options can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting of restricted stock units on June 12, 2025, is contingent upon the reporting person's continued service with the issuer.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future performance.

Stakeholder Impact

• The acquisition of shares and options by a director may positively influence shareholder sentiment.

Key Dates